The impact of p53 on aristolochic acid I-induced nephrotoxicity and DNA damage in vivo and in vitro

Mateja Sborchia1 · Eric G. De Prez2 · Marie-Hélène Antoine2 · Lucie Bienfait3 · Radek Indra4 · Gabriel Valbuena5 · David H. Phillips1 · Joëlle L. Nortier2 · Marie Stiborová4 · Hector C. Keun5 · Volker M. Arlt1

Received: 16 July 2019 / Accepted: 17 September 2019 / Published online: 10 October 2019
© The Author(s) 2019

Abstract
Exposure to aristolochic acid (AA) is associated with human nephropathy and urothelial cancer. The tumour suppressor TP53 is a critical gene in carcinogenesis and frequently mutated in AA-induced urothelial tumours. We investigated the impact of p53 on AAI-induced nephrotoxicity and DNA damage in vivo by treating Trp53(+/-), Trp53(+/−) and Trp53(−/−) mice with 3.5 mg/kg body weight (bw) AAI daily for 2 or 6 days. Renal histopathology showed a gradient of intensity in proximal tubular injury from Trp53(+/-) to Trp53(−/−) mice, especially after 6 days. The observed renal injury was supported by nuclear magnetic resonance (NMR)-based metabonomic measurements, where a consistent Trp53 genotype-dependent trend was observed for urinary metabolites that indicate aminoaciduria (i.e. alanine), lactic aciduria (i.e. lactate) and glycosuria (i.e. glucose). However, Trp53 genotype had no impact on AAI-DNA adduct levels, as measured by 32P-postlabelling, in either target (kidney and bladder) or non-target (liver) tissues, indicating that the underlying mechanisms of p53-related AAI-induced nephrotoxicity cannot be explained by differences in AAI genotoxicity. Performing gas chromatography–mass spectrometry (GC–MS) on kidney tissues showed metabolic pathways affected by AAI treatment, but again Trp53 status did not clearly impact on such metabolic profiles. We also cultured primary mouse embryonic fibroblasts (MEFs) derived from Trp53(+/-), Trp53(+/−) and Trp53(−/−) mice and exposed them to AAI in vitro (50 µM for up to 48 h). We found that Trp53 genotype impacted on the expression of NAD(P)H:quinone oxidoreductase (Nqo1), a key enzyme involved in AAI bioactivation. Nqo1 induction was highest in Trp53(+/-) MEFs and lowest in Trp53(−/−) MEFs; and it correlated with AAI-DNA adduct formation, with lowest adduct levels being observed in AAI-exposed Trp53(−/−) MEFs. Overall, our results clearly demonstrate that p53 status impacts on AAI-induced renal injury, but the underlying mechanism(s) involved remain to be further explored. Despite the impact of p53 on AAI bioactivation and DNA damage in vitro, such effects were not observed in vivo.

Keywords Aristolochic acid I · Tumour suppressor p53 · Mouse models · Carcinogen metabolism · DNA adducts · Mouse embryonic fibroblasts
Introduction

The p53 transcription factor acts as the “guardian of the genome” by inducing a wide range of tumour suppressive mechanisms (Lane 1992). These include DNA repair, apoptosis, cell cycle arrest and metabolic processes (Voussden and Lane 2007). p53 also acts as a “gatekeeper” by preventing proliferation of damaged cells transiently or permanently, and as a “caretaker” by controlling the repair of genetic alterations within the cell (Kruijswijk et al. 2015; Taneja et al. 2011). Given the wide range of cellular functions regulated by p53, it is inevitable that this protein plays an important role in a wide range of diseases, including cancer (Voussden and Lane 2007). p53 is deregulated in more than 50% of human cancers (Brosh and Rotter 2009; Freed-Pastor and Prives 2012). A disorder known as Li-Fraumeni syndrome, which was shown to be linked to germline mutations in TP53 and associated with an increased risk of cancer formation, further confirms the critical role played by p53 in tumour suppression (Malkin 2011). Also, Trp53(−/−) mice develop cancer with complete penetrance (Donehower et al. 1992; Jacks et al. 1994). The deregulation of p53 has also been linked to chemical exposures in the environment. In fact, different environmental carcinogens induce characteristic mutational patterns in TP53 (Olivier et al. 2010).

The environmental carcinogen AA is present in Aristolochia plants and can be found in medicinal herbal remedies (Gokmen et al. 2013; IARC 2012). The plant extract AA is a mixture of structurally related nitrophenanthrene carboxylic acids, mainly aristolochic acid I (AAI; Fig. 1a) and aristolochic acid II (AAII), with AAII being the major component (Arlt et al. 2002b; Heinrich et al. 2009). AA is the cause of aristolochic acid nephropathy (AAN) and Balkan endemic nephropathy (BEN) (Gokmen et al. 2013; Jadot et al. 2017; Jelakovic et al. 2019; Stiborova et al. 2016). Pathologically, AA-exposed individuals develop extensive interstitial nephropathy, which leads to end-stage renal failure and a high risk of developing upper urinary tract and bladder cancers (Cosyns et al. 1999; Lemy et al. 2008; Notier et al. 2000). More recently, AA exposure has also been linked to the development of renal cell carcinoma (Hoang et al. 2016; Turesky et al. 2016). The International Agency for Research on Cancer (IARC) has classified AA as carcinogenic to humans (Group 1) (IARC 2012). Since AA is hazardous to human health, many countries have banned Aristolochia-containing products from the market (Gokmen et al. 2013). However, the use of AA-containing herbal remedies remains a major concern for public health to date, particularly in Asia (e.g. China and Taiwan) (Grollman 2013).

AA requires metabolic activation before reacting with DNA and exerting its genotoxic effects (Schmeiser et al. 2015). Therefore, the metabolic activation of AA is a critical step in the formation of genotoxic metabolites.

**Fig. 1** a Metabolic activation and detoxication pathways of AAI. CYP, cytochrome P450; dA-N6-AAI, 7-(deoxyadenosin-N6-yl)aristolactam I; dG-N2-AAI, 7-(deoxyguanosin-N2-yl)aristolactam I; NQO, NAD(P)H:quinone oxidoreductase; POR, NADPH:cytochrome P450 oxidoreductase. b Schematic representation of experimental design. Trp53(+/+), Trp53(+/−) and Trp53(−/−) mice (n = 5/group) were treated with 3.5 mg/kg body weight (bw) AAI by intraperitoneal injection (i.p.) daily for 2 or 6 days. Controls were injected with water only. Mice were placed in metabolic cages on the last day of treatment and sacrificed 24 h later. For in vitro experiments, mouse embryonic fibroblasts (MEFs) were isolated from Trp53(+/+), Trp53(+/−) and Trp53(−/−) mouse embryos.
et al. 2009). AAI is activated by nitroreduction to generate N-hydroxyaristolactam I which can react with DNA to form pre-mutagenic adducts at adenine [i.e. 7-(deoxyadenosin-N6-yl)-aristolactam I (dA-AAI)] and guanine [i.e. 7-(deoxyguanosin-N2-yl)-aristolactam I (dG-AAI)] (Fig. 1a) (Stiborova et al. 2017). This nitroreduction is mainly catalysed by NQO1, cytochrome P450 (CYP) 1A1 and 1A2 (CYP1A1 and CYP1A2) and NADPH:cytochrome P450 oxidoreductase enzymes (Fig. 1a) (Stiborova et al. 2013, 2014a). The most abundant DNA adduct detected in AAN and BEN patients is dA-AAI (Arlt et al. 2011b). Furthermore, AT to TA transversions in the genomes of AA-exposed tumours (Hoang et al. 2013; Poon et al. 2013). These mutations are also frequently observed in the TP53 gene (Chen et al. 2012; Grollman et al. 2007), indicating a potential molecular mechanism associated with AA-induced carcinogenesis (Arlt et al. 2011b). Furthermore, AT to TA transversions were also induced in experimental cell culture models, including MEFs derived from Hupki (human TP53 knock-in) mice, exposed to AA (Kucab et al. 2019; Nedelko et al. 2009; Nik-Zainal et al. 2015). Given the clear link between AAI exposure and p53, it is important to study the role of this gene in AAI tumourigenesis. Previous studies have demonstrated that p53 can impact on carcinogen metabolism (Krais et al. 2016a, b; Willis et al. 2018; Wohak et al. 2016, 2018, 2019). It has also been shown that p53 impacts on the bioactivation of AAI in vitro (Simoes et al. 2008), a phenomenon which requires further investigations to better understand host factors modulating AAI-induced carcinogenesis.

To investigate the role of p53 in AAI-induced nephrotoxicity and DNA damage, Trp53(+/+), Trp53(+/−) and Trp53(−/−) mice were treated with AAI on the basis of a previously established protocol that studies experimental AAN. AAI-induced nephrotoxicity was investigated by performing histological and biochemical analyses on kidney and biofluids, respectively. DNA adduct formation and the activity of AAI metabolising enzymes were measured in kidneys to investigate the impact of p53 function on AAI bioactivation. Metabonomics-based experiments assessed metabolic changes attributable to kidney damage. Trp53(+/+), Trp53(+/−) and Trp53(−/−) MEFs were also employed as in vitro models to further explore the role of p53 in AAI bioactivation.

Materials and methods

Carcinogen

Aristolochic acid I (CAS Number: 10190-99-5; AAI; as sodium salt) was isolated as previously reported (Arlt et al. 2017).

Maintenance of Trp53(+/+) and Trp53(−/−) mice

Trp53(+/+) and Trp53(−/−) C57BL/6 mice were generated as previously reported (Jacks et al. 1994). More information about the Trp53<sup>3<sup>3<sup>mTyj</sup></sup> mouse strain can be found at www.jax.org/strain/002101. All animal experiments were carried out at King’s College London under licence in accordance with the Animal (Scientific Procedures) Act (1986), as amended by EU Directive 2010/63/EU, and with local ethical approval. Mice were bred at the Biological Services Unit at King’s College London by a Trp53(+/−) strategy to maintain the colony (9–11 weeks of age; n = 5/group) were treated with 3.5 mg/
kg bw AAI by intraperitoneal (i.p.) injection daily for 2 or 6 days (Fig. 1b). The dose to inject per mouse was determined by weighing the mice 1 day in advance or on the first day of the experimental protocol. Control mice (n = 5/group) were injected with water only. On days 2 or 6, mice were placed individually in metabolic cages to collect urine samples (approximately 1 ml) over 24 h. Mice were killed 24 h after the last treatment; and blood, kidneys, bladder and liver were collected. Tissues were snap frozen in liquid nitrogen and stored at −80 °C for further analysis. Vertically cut kidneys (whole) were individually placed in 4% paraformaldehyde in phosphate-buffered saline (PBS) at 4 °C. After 24 h, these were washed in 70% ethanol and processed for histology. The urine was centrifuged at 4 °C at 1600 × g for 15 min. The upper layer (i.e. serum) was stored at −20 °C for serum creatinine analysis and metabolite analysis by NMR. After collecting the blood (maximum 1 ml) with a syringe containing 0.5 M EDTA, it was centrifuged at 4 °C at 1600 × g for 15 min. The lower layer (i.e. serum) was stored at −20 °C for serum creatinine analysis.

**Histopathology**

Formalin-fixed (4% in PBS) and paraffin-embedded sections (4 µM thick) of tissue samples (n = 5/group) were attached to poly-l-lysine slides (Sigma-Aldrich). After air drying, the paraffin was removed from the tissue sections with xylene. Colouration by periodic acid-Schiff (PAS) was used for staining kidney samples. Slides were randomised and analysed blindly by optical microscopy. Sections were examined at low (200×) and high (400×) magnification for the presence of cellular injury, dysplasia, neoplasia, inflammation and fibrosis.

Basal glomerular and tubular membranes, and apical membrane brush border of proximal tubules from all PAS-stained kidney tissue samples were carefully examined. Considering the well-preserved structure of the basal membranes, attention was focused on lesions of variable intensity located on the proximal tubular epithelium. A semi-quantitative score of proximal tubular injury was developed and independently assessed by two investigators from the laboratory and one pathologist. The following scoring system was applied: 0—absence of any microscopical abnormality within the renal tissue; 1—proximal tubular injury limited to the loss of the brush border of the apical membrane; 2—necrotic proximal tubules in restricted areas; and 3—large areas of severely necrotic proximal tubules. For each histological sample, a mean quantification was calculated from the three investigators and considered as the final score of injury.

**Biochemical evaluation of renal function**

Renal function was determined by measuring creatinine levels by high-performance liquid chromatography (HPLC) in serum samples (n = 5/group) as previously reported (Baudoux et al. 2012). A calibration curve with standards containing 13.3–88.4 µmol/l creatinine (Sigma-Aldrich) was set up. The creatinine peak was used to quantify the amount of creatinine (mg/dl) within the serum samples. LAP enzyme activity was measured with a spectrofluorometric assay in urine samples (n = 3/group). Urinary excretion of this enzyme is used as an indicator of the integrity of the proximal tubular brush border (Lebeau et al. 2005). Urine samples (100 µl with glycerol) were diluted 1:30 and 1:60 with 50 mM Tris–HCl buffer (pH 7.6). The substrate leucine-7-amido-4-methyl coumarin (Leu-AMC; Bachem) was incubated with the diluted samples at 37 °C for 60 min. The reaction was terminated by heating the samples at 95 °C for 5 min. Fluorescence of free AMC was measured at 367 nm (excitation) and 440 nm (emission). LAP activity was normalised against urine creatinine (U/g urine creatinine). Creatinine levels in urine (100 µl) were measured using the Jaffé method (Creatinine Diagnostic Kit, Sigma-Aldrich).

**Metabonomics: NMR analysis of urine**

Mouse urine samples (n = 3/group) prepared for NMR were run on a BrukerAvance 400 spectrometer operating at 400 MHz 1H NMR frequency. Briefly, 200 µl of urine was mixed with 340 µl of a buffer (pH 7.4) consisting of 75 mM KH2PO4 and 15.4 mM sodium azide, and centrifuged at 12,000 rpm (5424R, Eppendorf™) for 30 s at 4 °C. To each sample, 60 µl of a buffer (pH 7.4) consisting of 1.5 M KH2PO4, 2 mM sodium azide and 6.8 mM 3-(trimethylsilyl)-[2,2,3,3-4]propionic acid sodium salt (TSP-d4) were added, with TSP-d4 being used as an internal standard. Following mixing, samples were centrifuged at 12,000 rpm for 5 min at 4 °C. The prepared urine samples were transferred into individual 5 mm NMR tubes (HP507, NORELL®,) which were capped and stored at 4 °C until analysis. The generated NMR data were analysed as previously reported (Maître et al. 2017). In brief, NMR spectra were imported into MATLAB (MathWorks®) and normalised against the internal creatinine peak, and results were reported as metabolite levels (i.e. excretion in urine relative to creatinine).

**DNA isolation from mouse tissue**

DNA from kidney, liver and bladder tissue (n = 4/group) was isolated by a standard phenol–chloroform extraction
method. The concentration and purity (260/280 ratio of 1.8-2) of the DNA were measured with a NanoDrop™ 2000
Spectrophotometer.

DNA adduct analysis by 32P-postlabelling

DNA adducts were determined using the nuclease P1 enrichment version of the 32P-postlabelling assay as previously described (Arlt et al. 2017; Schmeiser et al. 2013). DNA samples (4 µg) were digested with micrococcal nuclease (240 mU, Sigma-Aldrich) and calf spleen phosphodiesterase (60 mU, Calbiochem) for 3 h at 37 °C; and enriched and labelled as reported. For separation by multidirectional thin-layer chromatography (TLC) on polyethyleneimine-cellulose sheets (Macherey–Nagel), the following solvents were used: D1 (1 M sodium phosphate, pH 6.0); D3 (3.5 M lithium formate, 8.5 M urea, pH 4.0); and D4 (0.8 M lithium chloride, 0.5 M Tris, 8.5 M urea, pH 9.0). DNA adducts were visualised by scanning the TLC plates with Instant Imager (Canberra Packard, Dowers Grove) technology. Quantitative analysis was performed as previously described (Phillips and Arlt 2014) and results were expressed as DNA adducts/10⁸ normal nucleotides. AA-DNA adducts were identified using reference compounds as previously described (Schmeiser et al. 1996).

Preparation of microsomes and cytosols from mouse tissue

Microsomes and cytosols were isolated from untreated (control) and AAI-treated kidney tissues as previously described (Arlt et al. 2008). Microsomal and cytosolic fractions were isolated from pooled tissues (n = 5/group), snap frozen in liquid nitrogen and stored at −80 °C for further analysis. The bicinechonic acid (BCA) protein assay, with bovine serum albumin (BSA) as a standard, was used to measure protein concentrations in the isolated fractions. Pooled fractions were used for further experiments.

Immunoblotting

To evaluate the expression of DNA damage response proteins (i.e. p53, p21 and H2ax), whole protein extracts from kidney tissues were prepared as previously described (Krais et al. 2016a). Microsomal and cytosolic fractions were used to determine Cyp1a1 and Nqo1 protein expression, respectively. Western blotting was carried out as previously reported (Kucab et al. 2012). Briefly, protein samples (25 µg and 10 µg of protein for tissue lysates and microsomes or cytosols, respectively) were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis using 4–12% gels. Following separation, proteins were transferred onto a nitrocellulose membrane (Bio-Rad) and successful transfer was checked by Ponceau Red (Sigma-Aldrich) staining. After blocking, the following primary antibodies were used overnight at 4 °C: p53 (1:1000; Cell Signalling); p21 (1:2000; BD), H2ax (1:1000; Cell Signalling); Cyp1a1 (1:1000; provided by Dr. Colin Henderson, University of Dundee); and Nqo1 (1:5000, Sigma-Aldrich). Glyceraldehyde phosphate dehydrogenase (Gapdh; 1:25,000; Chemicon) served as a loading control. Following incubations with primary antibodies, blots were incubated with appropriately diluted species-specific horse radish peroxidase-conjugated secondary antibodies (anti-mouse or anti-rabbit; Bio-Rad) for 1 h at room temperature. Proteins were detected by chemiluminescence. Amersham™ ECL™ Western Blotting Detection Reagents (GE Healthcare Life Sciences) was used according to the manufacturer’s instructions and membranes were exposed to Amersham Hyperfilm™ ECL™ (GE Healthcare Life Sciences).

Enzyme activity assays

7-Ethoxyresorufin O-deethylation (EROD) was used to characterise Cyp1a enzyme activity in microsomal fractions (Stiborova et al. 2012). EROD activity was expressed as the amount of resorufin (pmol) produced per concentration of protein (mg/ml) per minute.

Nqo1 activity was measured using menadione (2-methyl-1,4-naphthoquinone) as a substrate as previously reported, and the assay was improved by the addition of cytochrome c (Levova et al. 2012). Nqo1 activity was expressed as the amount of reduced cytochrome c (nmol) produced per the concentration of protein (mg/ml) per minute.

RNA isolation from mouse tissue

Total RNA was isolated from kidney tissues (n = 5/group) by a modified method based on both TRIzol® (Thermo Fisher Scientific) and RNeasy Mini Kit (QIAGEN) protocols. A portion of tissue (15–35 mg) was placed in a tube containing a steel bead and 1 ml of TRIzol®. The tissue was homogenised twice with a TissueLyser II at 25 Hz for 2 min and it was placed at room temperature for 5 min. Following the addition of 200 µl of chloroform, it was centrifuged at 4 °C at 13,000 rpm (5,424 R, Eppendorf™) for 20 min. The top layer was transferred to a tube and mixed with 350 µl of 70% ethanol. The sample was transferred to an RNase-Free DNase Set (QIAGEN) and subsequent RNA isolation steps were performed according to the manufacturer’s instructions. On-column DNase digestion with an RNase-Free DNase Set (QIAGEN) was also performed according to the manufacturer’s instructions. The concentration and purity (260/280 ratio of 2) of the RNA were measured with a NanoDrop™ 2000 Spectrophotometer. The total RNA was stored at −80 °C.
for quantitative real-time polymerase chain reaction (qRT-PCR) analysis.

Gene expression analysis by qRT-PCR

RNA was reverse transcribed into cDNA with a High-Capacity RNA-to-cDNA™ Kit (Thermo Fisher Scientific). qRT-PCR was performed according to the manufacturer’s instructions using a 2X TaqMan™ Gene Expression Master Mix (Thermo Scientific). The Roche Universal Probe Library was used to design intron-spanning assays (i.e. primers and matching probe) for the following NCBI sequences: NM_009992.4 and NM_001136059.2 (Cyp1a1); and NM_008706.5 (Nqo1). Gene expression was analysed according to the manufacturer’s instructions with a 7500 Fast Real-Time PCR System (Applied Biosystems). Relative gene expression was normalised to the housekeeping gene Gapdh (NM_001289726.1) and analysed by the comparative threshold cycle (Ct) method. Results were reported as the fold change in gene expression between the treated and untreated (control) samples (2−ΔΔCt method).

Metabonomics: GC–MS analysis of mouse tissue

Changes in kidney tissue metabolites (n = 5/group) were analysed by GC–MS. Frozen tissues (20–25 mg) were transferred into screw-cap tubes containing glass beads and 800 µl of cold 80% LC–MS CHROMASOLV methanol (Sigma-Aldrich). Tissues were disrupted twice with a Precellys® Evolution homogeniser at 6500 rpm for 20 s. Following centrifugation at 12,000 rpm for 5 min at 4 °C (5424R, Eppendorf™), the supernatant was collected in 2 ml tubes. This metabolite extraction was repeated once more. Obtained samples were dried under nitrogen and stored at −80 °C for further analysis.

A chloroform (HPLC grade; Sigma-Aldrich)–methanol (2:1) solution (300 µl) was added to each sample on ice and these were vortexed at room temperature at maximum speed for 5 s. LC–MS CHROMASOLV water (300 µl; Sigma-Aldrich) was added to each sample on ice and these were vortexed at room temperature at maximum speed for 5 s. Samples were centrifuged at 12,000 rpm for 10 min at 4 °C. Aqueous and organic phases were transferred into silanised GC–MS glass vials (Agilent Technologies). This dual-phase extraction was repeated once more. Aqueous and organic phases were transferred into the corresponding GC–MS vials. In preparation for derivatisation, 10 µl of myristic acid (Sigma-Aldrich) was added to the samples. Aqueous phases were dried overnight in the following manner: vials were individually sealed with parafilm punctured several times with a needle, placed in liquid nitrogen and a BenchTop Pro with Omnitronics Freeze Dryer (SP Scientific). Organic phases were dried under nitrogen.

Aqueous phases were derivatised by adding 20 µl of a ready-made methoxyamine solution (Thermo Fisher Scientific) to each sample. Samples were incubated at 30 °C for 500 rpm for 90 min. Then, 80 µl of N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA; Thermo Fisher Scientific) was added to each sample and incubated at 37 °C for 500 rpm for 30 min. The liquid in each vial was transferred to a silanised glass insert (Agilent Technologies) within a GC–MS vial for GC–MS analysis.

Organic phases were derivatised by adding 300 µl of a 1:1 methanol-toluene (Sigma-Aldrich) solution and 200 µl of 0.5 M sodium methoxide (in methanol; Sigma-Aldrich) to each sample. Samples were left at room temperature for 1 h. The transmethylation of lipid was stopped by adding 500 µl of 1 M NaCl and 20 µl of concentrated HCl to each sample. Lipid extraction was initiated by adding 500 µl of hexane (Sigma-Aldrich). The top organic layer was transferred to a new GC–MS vial containing magnesium sulphate (Sigma-Aldrich) and the extraction process was repeated once more. Supernatants were combined accordingly, transferred to new GC–MS vials and dried under nitrogen. To derivatise free fatty acids, 40 µl of acetonitrile (Sigma-Aldrich) and 40 µl of MSTFA were added to each sample. Samples were vortexed and spun down briefly before being placed at 37 °C at 350 rpm for 30 min. The liquid in each vial was transferred to a silanised glass insert as described above before commencing GC–MS analysis.

The quality of the technical steps described above was assessed by incorporating a dual-phase extraction blank in both the aqueous and organic phase GC–MS runs. In addition, the quality of the GC–MS runs was determined by injecting quality control (QC) samples (aqueous or organic) after every sixth sample. Such QC samples were created during dual-phase extraction by combining 50 µl or 25 µl of each aqueous or organic phase, respectively. Metabolite chromatograms obtained by GC–MS were analysed against the Automated Mass Spectral Deconvolution and Identification System (AMDIS) database in MATLAB®. Spline normalisation was performed against the QC samples in MATLAB®. The data were normalised against tissue weight and results were reported as metabolite levels.

Isolation and culture of Trp53(+/+), Trp53(+/−) and Trp53(−/−) MEFs

MEFs were isolated from day 13.5 embryos according to a modified protocol as previously described (Kucab et al. 2015). MEFs were genotyped from embryos as described above, and cell stocks were stored in liquid nitrogen. MEFs were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) with high glucose, GlutaMAX™ and pyruvate (Thermo Fisher Scientific), supplemented with 10% foetal...
bovine serum (FBS) and 100X penicillin–streptomycin. Cells were cultured at 37 °C in 5% CO₂ and 3% O₂ for a maximum of 14 days as the cells eventually senesce (Sherr and De Pinho 2000). Following MEF isolation, growth curves were set up for Trp53(+/−), Trp53(+/+) and Trp53(−/−) MEFs to determine appropriate seeding densities for experiments spanning 72 h. Trp53(+/+) cells doubled over approximately 30 h, whereas Trp53(+/−) and Trp53(−/−) cells doubled over approximately 24 h (data not shown). On the basis of these findings, Trp53(+/+) and Trp53(+/−) and Trp53(−/−) MEFs were plated at a seeding density of 3 × 10⁴, 2 × 10⁴ and 2 × 10⁴ cells/cm² (24 h), respectively; or 1.5 × 10⁵, 1 × 10⁵ and 1 × 10⁴ cells/cm² (48 h), respectively.

**The impact of Trp53 status on AAI bioactivation in MEFs**

Viability of MEFs after AAI exposure for 24 and 48 h was determined with the crystal violet staining assay as previously described (Kucab et al. 2012). Three concentrations of AAI (10, 50 and 100 µM in water) were tested on the basis of previously published studies (Feldmeyer et al. 2006; Liu et al. 2004; Nedelko et al. 2009). Crystal violet (4[4-dimethylaminophenyl]-phenyl-methyl]-N,N-dimethyl-aniline; Sigma-Aldrich) is a dye that stains proteins and DNA. The relative density of the adherent cell culture is a function of the amount of crystal violet staining. Briefly, cell medium was removed from the 96-well cell culture plate and wells were rinsed with 150 µl of PBS. Cells were incubated for 15 min with 30 µl of 0.1% crystal violet per well. Following crystal violet removal, wells were washed with 200 µl of PBS and the plate was allowed to air dry overnight in the dark. At the time of measurement, 100 µl of 50% ethanol was added per well and the absorbance was read at 595 nm on an ELx800 plate reader (BioTek). Cell viability was expressed as the percentage of survival of exposed cells in comparison to the respective control cells. On the basis of the cytotoxicity data, subsequent experiments were carried out solely with 50 µM AAI.

For DNA adduct analysis, MEFs were plated in T75 cm² flasks and exposed to 50 µM AAI for 24 and 48 h. Control cells were exposed to water only. Cell pellets were collected and washed with PBS; and RNA was isolated with the RNeasy Mini Kit (QIAGEN) according to the manufacturer’s instructions. qRT-PCR analysis was performed as described above.

**Statistics**

The data are presented as mean ± SD, with the sample size dependent on the type of experimental analysis. Statistical analysis was performed with GraphPad Prism 6 software. ANOVA was used to compare three or more groups of data. One-way ANOVA and Tukey’s post hoc test were used when one variable was being compared between three or more groups of data. Two-way ANOVA and Bonferroni’s post hoc test were used when two variables were being compared between three or more groups of data. Results marked with an asterisk (*) indicate comparisons between a treated group to a control group or as otherwise indicated. Results marked with a number sign (#) indicate comparisons to the Trp53(+/+) group within the treatment group taken into consideration. The following p values were used to determine significance: */(# or #) p ≤ 0.05, **(or ###) p ≤ 0.01, ###(or ####) p ≤ 0.001, ####(or #####) p ≤ 0.0001.

**Results**

**The impact of Trp53 status on AAI-induced tissue damage**

To investigate the impact of Trp53 on AAI-induced tissue damage and toxicity, kidney tissues obtained from AAI-treated Trp53(+/+), Trp53(+/−) and Trp53(−/−) mice were analysed by histopathology. Representative photomicrographs (400 x magnification) for kidneys are shown in Fig. 2a. Discrepancies in colours between photomicrographs were simply due to staining or the settings of the optical microscope. PAS staining delineates both the apical brush border and basal membrane of the proximal tubular epithelium (shown in dark pink in the photomicrographs).

At both 2 and 6 days, the proximal tubules in untreated (control) Trp53(+/+), Trp53(+/−) and Trp53(−/−) kidneys were found to be of normal structure. After treatment with AAI for 2 days, Trp53(+/+) kidneys were normal. However, at the same time point, there was an indication of mild or mild-to-moderate proximal tubular injury in AAI-exposed Trp53(+/−) kidneys. This injury was characterised by local detachment of the brush border membrane. However, proximal tubular necrosis was not found. In Trp53(−/−) kidneys, moderate-to-severe tubular injury...
was observed. In some, but not all \( Trp53(-/-) \) kidneys, areas of proximal tubular necrosis were found. After treatment with AAI for 6 days, a gradient of intensity in proximal tubular lesions from \( Trp53(+/+) \) to \( Trp53(+/-) \) kidneys and then to \( Trp53(-/-) \) kidneys was evident. Proximal tubular injury was isolated in \( Trp53(+/+) \) kidneys and it consisted of the disappearance of the brush border membrane. Renal injury in \( Trp53(+/-) \) mice was characterised by severe lesions of necrosis. In these mice, the lumen of the proximal tubules was obstructed by debris; however, oedema or inflammatory infiltrate were not present. In \( Trp53(-/-) \) kidneys, proximal tubular injury and necrosis
were both extensive and severe. Atrophic proximal tubules were also noted. Such tubules are unable to regenerate the brush border membrane and appear pseudo-dilated. At a lower magnification (Fig. S2; 200× magnification), areas with both damaged and intact proximal tubules were observed in AAI-exposed Trp53/(−+/−) and Trp53/(−/−) kidney sections. A lower number of proximal tubules, however, kept their normal structure in Trp53/(−/−) kidneys.

Given the renal injury in AAI-treated Trp53/(+/+), Trp53/(+−) and Trp53/(−−) mice at both 2 and 6 days, kidney tissue sections were semi-quantitatively scored (Fig. 2b). As expected, a score of 0 was given to untreated (control) Trp53/(+/+), Trp53/(−+) and Trp53/(−−) kidneys at both 2 and 6 days. The scores attributed to AAI-exposed Trp53/(+−), Trp53/(+−) and Trp53/(−−) kidneys were reflective of the histopathology noted in Fig. 2a. More precisely, the proximal tubular injury was most severe in Trp53/(−−) kidneys at both 2 and 6 days. The differences in renal injury between Trp53/(−−) (i.e. score of 2.8) and Trp53/(+−) (i.e. score of 1.9) kidneys were most significant at 6 days. Overall, histopathological scores revealed that wild-type (WT) Trp53 protects from AAI-induced proximal tubular damage.

To monitor the toxicity of AAI in mice, body weights of Trp53/(+−), Trp53/(+−) and Trp53/(−−), mice treated with AAI for 2 or 6 days were measured (Fig. S3). Whilst AAI treatment for 2 days had no effect on weight, a slight decrease in weight was observed for Trp53/(+−), Trp53/(+−) and Trp53/(−−) mice treated with AAI for 6 days. However, this change in weight (from day 0 to day 6) was not statistically significant.

Since kidney injury was most prominent after 6 days of AAI treatment, further investigations related to the role of Trp53 in AAI-induced nephrotoxicity and DNA damage solely focused on this time point.

The impact of Trp53 status on markers of AAI-induced nephrotoxicity

To further investigate the impact of Trp53 on AAI-induced nephrotoxicity, creatinine levels were measured by HPLC analysis in serum. As expected, serum creatinine levels were low in untreated (control) mice but increased after AAI treatment (Fig. 2c). However, this increase was only significant for AAI-treated Trp53/(+−) and Trp53/(−−) mice, with serum creatinine levels being the highest in Trp53/(−−) mice.

Urinary LAP enzyme activity was used as a marker to assess renal proximal tubular damage. LAP enzyme activity was low in urine of untreated (control) mice. Urinary LAP activity only significantly increased in AAI-treated Trp53/(+−) mice in comparison to the respective control and AAI-treated Trp53/(+−) mice (Fig. 2d). In AAI-treated Trp53/(−−) mice, LAP activity appeared to be slightly higher relative to AAI-treated Trp53/(+−) mice, but this effect was not statistically significant.

A metabolic approach was also used to further investigate markers of AAI-induced renal injury in urine. NMR spectra for nine metabolites were selected for analysis. These included alanine, α-ketoglutarate, citrate, glucose, lactate, succinate, trimethylamine, formate and fumarate. Interestingly, alanine, glucose and lactate levels increased after AAI treatment (Fig. 2e). These changes were solely significant in AAI-treated Trp53/(+−) and Trp53/(−−) mice in comparison to their respective controls. There also seemed to be an emerging pattern in which levels of these urinary metabolites (i.e. alanine, glucose and lactate) increased in a Trp53 genotype-dependent manner, with the lowest levels in Trp53/(+−) mice and the highest levels in Trp53/(−−) mice. However, these changes were not statistically significant. Interestingly, succinate and trimethylamine levels decreased in urine (Fig. S4), with succinate levels significantly lower in AAI-treated Trp53/(+−) and Trp53/(−−) mice compared to controls, and trimethylamine levels significantly lower in AAI-treated Trp53/(+−), Trp53/(+−) and Trp53/(−−) mice. Moreover, urinary trimethylamine levels were significantly higher in AAI-treated Trp53/(+−) mice relative to AAI-treated Trp53/(+−) mice. In contrast, no significant changes in α-ketoglutarate, citrate, fumarate and formate levels were observed (Fig. S4).

The impact of Trp53 status on AAI-induced DNA damage

The adduct pattern induced by AAI in liver, kidney and bladder was qualitatively similar in Trp53/(+−), Trp53/(+−) and Trp53/(−−) mice. The pattern consisted of two major adduct spots, previously identified (Schmeiser et al. 2009) as dA-AAI (spot 1) and dG-AAI (spot 2) (Fig.
S5a). In addition, one minor adduct was detected, previously identified (Schmeiser et al. 2009) as 7-(deoxyadenosin-N6-yl)-aristolactam II (dA-AAII; spot 3) (Fig. S5a). These adducts (i.e. dA-AAI, dG-AAI and dA-AAII) have been found in urothelial tissue of AAN patients (Nortier et al. 2000; Schmeiser et al. 2014; Stiborova et al. 2017). No DNA adducts were detected in untreated (control) tissues (data not shown). AAI-induced DNA adduct levels were the highest in kidney, with levels being ~2.5-fold higher in kidney relative to both bladder and liver (Fig. 3). However, no differences were observed in DNA adduct formation between Trp53(+/+), Trp53(+/−) and Trp53(−/−) mice.

**The impact of Trp53 status on AAI-induced DDR**

The expression of DDR proteins was investigated in kidney tissue lysates. p53 expression was not detected in Trp53(+/+), Trp53(+/−) and Trp53(−/−) kidneys (Fig. 4a). Observed bands in the range of interest were unspecific and close to the expected p53 bands. However, film exposure for shorter and longer periods of time ascertained that p53 is undetectable. p21 expression was also not detected in untreated (control) kidneys, whereas weak induction was noticeable in AAI-exposed kidneys (Fig. 4a). As a marker of DNA damage, particularly the formation of double-strand breaks (Dickey et al. 2009), expression of histone H2A family member X (H2ax) was presented as mean ± SD derived from independent in vitro measurements (n=3/group).

---

Fig. 3  AAIf-DNA adduct formation (RAL, relative adduct labelling) in a liver, b kidney and c bladder at 6 days was determined by the nuclease P1-enrichment version of the 32P-postlabelling method. Results are presented as mean ± SD (n=4 mice/group).

Fig. 4  a Protein expression in AAI-exposed mouse kidneys. Western blot analysis of p53, p21 and H2ax expression in kidney tissue from AAI-treated (6 days) Trp53(+/+), Trp53(+/−) and Trp53(−/−) mice. Nqo1 and Cyp1a1 expression was investigated in AAI-exposed (6 days) kidney cytosols and microsomes, respectively. Gapdh expression was used as a loading control. Representative images of Western blots are shown; at least duplicate analyses from independent experiments were performed. b Enzyme activity in AAI-exposed mouse kidneys. Cyp1a activity at 6 days (upper panel) was determined by the EROD assay. Results are presented as mean ± SD derived from independent in vitro measurements (n=3/group). c Gene expression in AAI-exposed mouse kidneys. The fold change for Cyp1a1 (upper panel) and Nqo1 (lower panel) is the fold change in expression relative to the control for each genotype. Gene expression was determined by qRT-PCR and the 2−ΔΔCt method (n=5 mice/group). Statistical analysis was performed by two-way ANOVA and Bonferroni’s post hoc test (**p ≤ 0.01, ****p ≤ 0.0001, comparison as indicated); and by one-way ANOVA and Tukey’s post hoc test (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001, in comparison to Trp53(+/+) within that treatment group).
investigated. H2ax was induced in AAI-exposed kidneys, whereas such effect was not found in respective controls (Fig. 4a). H2ax induction seemed to be higher in AAI-exposed Trp53(−/−) kidneys in comparison to AAI-exposed Trp53(+/+) and Trp53(+/-) kidneys.

The impact of Trp53 status on the expression of AAI metabolising enzymes

Nqo1 and Cyp1a1 protein expression was investigated in kidney cytosols and microsomes, respectively. Nqo1 was induced in AAI-exposed Trp53(+/+) and Trp53(+/-) kidney cytosols relative to controls, whereas no such induction was observed in AAI-exposed Trp53(−/−) kidney cytosols (Fig. 4a). Cyp1a1 was not detected at the protein level in kidney microsomes (Fig. 4a). In contrast, Cyp1a enzyme activity was detectable in kidney microsomes, but it was relatively low (Fig. 4b). Basal Cyp1a activity was Trp53 genotype dependent and significantly altered by AAI treatment. Cyp1a enzyme activity was significantly lower in AAI-exposed Trp53(+/-) and Trp53(−/−) kidneys relative to AAI-exposed Trp53(+/+) kidneys. It also significantly decreased in AAI-exposed Trp53(+/-) kidneys in comparison to controls, whilst the activity of Cyp1a in AAI-exposed Trp53(+/+) and Trp53(−/−) kidneys significantly increased relative to controls. Nqo1 enzyme activity was measured in kidney cytosols (Fig. 4b). In general, Nqo1 enzyme activity was relatively high. Nqo1 activity appeared to be dependent on Trp53 genotype and treatment, with the lowest activity in AAI-exposed Trp53(−/−) kidneys relative to AAI-exposed Trp53(+/-) kidneys, but observed changes were not statistically significant. Cyp1a1 and Nqo1 expression was also investigated in kidney tissues at the gene level by qRT-PCR (Fig. 4c). No significant induction in Cyp1a1 expression was observed after AAI treatment. In contrast, Nqo1 expression was significantly lower in AAI-exposed Trp53(−/−) kidneys relative to AAI-exposed Trp53(+/+) kidneys, thus reflecting findings at the protein level in AAI-exposed kidney cytosols.

The impact of Trp53 status on kidney tissue metabolite profiles after AAI treatment

An additional metabolomic method, GC–MS, was used to detect changes in metabolite levels in kidneys of AAI-treated Trp53(+/+), Trp53(+/-) and Trp53(−/−) mice. A total of 72 and 25 metabolites were detected in aqueous (Table S2) and organic (Table S3) phases, respectively. For most metabolites, levels were highly variable between genotype or treatment groups and unaffected by AAI treatment. However, 11 metabolites detected in the aqueous phase of AAI-exposed kidneys displayed significant changes following AAI treatment (Fig. 5): 3-indolelactic acid 2, xanthurenic acid, citric acid, cytidine-5'-monophosphate 1, hippuric acid 2, l-allo-threonine 1, l-leucine 1, l-lysine 2, l-threonine 1, norvaline 1 and uric acid 1. For ten out of these 11 metabolites, levels significantly increased after AAI treatment in most genotype groups. Interestingly, 3-indolelactic acid 2 (Fig. 5a), citric acid (Fig. 5c), hippuric acid 2 (Fig. 5e) and l-allo-threonine 1 (Fig. 5f) levels were significantly lower in AAI-exposed Trp53(+/-) kidneys compared to AAI-exposed Trp53(+/+) kidneys. A different trend was observed for cytidine-5'-monophosphate 1 (Fig. 5d). More precisely, the levels of this metabolite significantly decreased in AAI-exposed Trp53(+/-), Trp53(+/-) and Trp53(−/−) kidneys compared to respective controls. Only one metabolite from the organic phase of AAI-exposed kidneys was affected by AAI treatment. More precisely, methyl palmitate levels significantly decreased in AAI-exposed Trp53(+/-), Trp53(+/-) and Trp53(−/−) kidneys (Fig. 5i). Overall, AAI treatment impacted on the level of certain metabolites in kidney tissue. Despite observing a pattern in metabolite levels for AAI-exposed Trp53(+/-) kidneys, Trp53 genotype did not majorly impact on tissue metabolite levels after AAI treatment.

The impact of Trp53 status on AAI bioactivation and DNA damage in MEFs

To determine cell viability following AAI exposure, Trp53(+/+), Trp53(+/-) and Trp53(−/−) MEFs were exposed to 10, 50 and 100 µM AAI for 24 and 48 h (Fig. 6a). Exposure to 10 µM AAI for 24 and 48 h did not lead to cytotoxicity in MEFs. Cell viability was only slightly affected in MEFs at 50 µM AAI for 24 h (> 60% viability), but cell survival decreased at this concentration at 48 h (< 60% viability). Exposure to 100 µM AAI was highly cytotoxic (≤ 60% viability) at both 24 and 48 h in MEFs. Trp53 genotype did not significantly impact on cell viability at any of the tested AAI concentrations and time points. To study the effects of AAI on DNA damage in MEFs, 50 µM AAI was selected for further experiments.

As expected, p53 and p21 were expressed in Trp53(+/+) and Trp53(+/-) MEFs, but not in Trp53(−/−) MEFs (Fig. 6b). p53 was highly induced in AAI-exposed Trp53(+/-) MEFs. p53 protein was also highly induced in AAI-exposed Trp53(+/-) MEFs, but at lower levels in comparison to Trp53(+/-) MEFs. p21 was also induced over 48 h in AAI-exposed Trp53(+/-) and Trp53(+/-) MEFs, with no striking differences in p21 levels between Trp53(+/-) and Trp53(+/-) MEFs. AAI treatment induced DNA adducts and the pattern observed in Trp53(+/-), Trp53(+/-) and Trp53(−/−) MEFs was qualitatively similar. The pattern consisted of two major adduct spots, previously identified (Schmeiser et al. 2009) as dA-AAI (spot
1) and dG-AAI (spot 2) (Fig. S5b). The same AAI-DNA adducts were formed in vivo (Fig. S5a). No DNA adducts were detected in untreated (control) MEFs (data not shown). AAI-DNA adduct levels were not significantly different between Trp53(+/+), Trp53(+/−) and Trp53(−/−) MEFs at 24 h (Fig. 6c). However, at 48 h, adduct levels were significantly lower in Trp53(−/−) MEFs in comparison to Trp53(+/+) MEFs after AAI treatment. In addition, adduct levels in Trp53(−/−) MEFs exposed to AAI for 48 h were significantly lower in comparison to those exposed for 24 h.

Expression of Nqo1 and Cyp1a1 in MEFs was investigated both at the protein (Fig. 6b) and gene (Fig. 6d) levels. Interestingly, unlike for AAI-exposed Trp53(−/−) MEFs, Nqo1 was highly induced at both 24 and 48 h in AAI-exposed Trp53(+/+) and Trp53(+/−) MEFs (Fig. 6b). At 48 h, these findings correlated with the observed adduct levels in Trp53(−/−) MEFs exposed to AAI for 48 h were significantly lower in comparison to those exposed for 24 h.

Fig. 5 Metabolite levels in kidney tissues of AAI-treated mice (6 days). a 3-indolelactic acid 2, b xanthurenic acid, c citric acid, d cytidine-5′-monophosphate 1, e hippuric acid 2, f l-allothreonine 1, g l-leucine 1, h l-lysine 2, i l-threonine 1, j norvaline 1, k uric acid 1 and l methyl palmitate levels (arbitrary units) in kidney tissues were measured by GC–MS. Results are presented as mean ± SD (n=5 mice/group). Statistical analysis was performed by two-way ANOVA and Bonferroni’s post hoc test (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001, comparison as indicated); and by one-way ANOVA and Tukey’s post hoc test (*p ≤ 0.05, in comparison to Trp53(+/+) within that treatment group)
Trp53/Trp53 (+) and significantly decreased from 24 to 48 h in both 24 and 48 h (Fig. 6d). However, Cyp1a1 was not detected at the protein level (+/−) previously described (Baudoux et al. 2012), but not significantly altered, between Trp53(+/+) and Trp53(+/−) MEFs at both 24 and 48 h (Fig. 6d). However, Cyp1a1 levels significantly decreased from 24 to 48 h in both Trp53(+/+) and Trp53(+/−) MEFs.

Discussion

The impact of Trp53 status on AAI-induced tissue damage

In experimental animals, treatment with higher doses of AA leads to necrosis in proximal tubules, a histopathological feature also seen in AAN patients. For example, daily i.p. treatment with 5 mg/kg bw AA over 8 days (Baudoux et al. 2012) or oral treatment with 5 mg/kg bw AAI over 21 days (Arlt et al. 2011b) led to necrosis in proximal tubules in mice. Renal necrosis was also observed in another rodent model, in which rats were treated with subcutaneous injections of either 10 mg/kg bw AA for 10 days (Debelle et al. 2002) or 15 mg/kg bw AA for 5 days (Pozdzik et al. 2016). In the present study, experimental AAN was studied in mice as previously described (Baudoux et al. 2012), but Trp53(+/+), Trp53(+/−) and Trp53(+/−) mice were treated with a daily i.p. dose of 3.5 mg/kg bw AAI, instead of 5 mg/kg bw, in order to minimise necrotic lesions in kidneys (Nortier et al., unpublished observation). The chosen time points (2 and 6 days) in the present study were also based on previous work (Baudoux et al. 2012) and selected to monitor acute AAI-induced nephrotoxicity over time. As performed previously (Baudoux et al. 2012), only male mice were used in the present study. It was not possible to conduct experiments on female mice because female Trp53(−/−) mice appeared to have high mortality soon after birth. It is noteworthy that previous work on mice, which were treated with 5 mg/kg bw AA for 21 days, led to tumour formation in the forestomach, kidneys, lungs, uterus and lymphoid organs within 56 weeks (Mengs et al. 1982). In the present study, AAI-exposed kidneys appeared macroscopically abnormal, especially at 6 days and in Trp53(−/−) mice (data not shown). In addition, AAI-treated Trp53(−/−) mice presented early signs of sickness (e.g. lethargy, loss of appetite, impaired movement) towards day 6. Thus, AAI treatment for more than 6 days at the selected dose was not considered for ethical reasons. Moreover, at 6 days, Trp53(−/−) mice tended to excrete urine that was lighter in colour, indicating some form of diuresis.

The kidneys act as filters by removing toxic waste from the blood through glomerular filtration (Scott and Quaggin 2015). The membranes of epithelial cells (e.g. proximal tubular cells) within the kidney both reabsorb beneficial and secrete unwanted metabolites. Hence, proximal tubular cells come into close contact with xenobiotics, including nephrotoxic compounds (Nicholson et al. 2002). AA primarily targets proximal tubules in human kidney (Nortier and Vanherwegem 2002). Experimentally, AA uptake was confirmed in vitro (i.e. by opossum kidney proximal tubular cells) (Lebeau et al. 2001). It was shown that organic anion transporters mediate uptake of AA into proximal tubular cells and thereby participate in renal cell damage (Bakhiya et al. 2009; Dickman et al. 2011; Xue et al. 2011). The histopathology findings in the present study clearly showed that prolonged AAI treatment (i.e. 6 days) damages kidneys, especially renal proximal tubular cells. Similar histopathological damage was also shown in previous rodent studies (Arlt et al. 2011b; Baudoux et al. 2012; Debelle et al. 2002, 2003; Pozdzik et al. 2016). Apart from proximal tubular necrosis, both atrophy and fibrosis with a lymphocytic infiltrate were present (Baudoux et al. 2012). In addition, the latter study showed that the brush border of proximal tubules presented with disruptions and detachment. Other studies also demonstrated that glomeruli remain intact after AA treatment (Debelle et al. 2003), which is in accordance with the findings in the present study.

In the present study, proximal tubular damage depended on Trp53 status. More precisely, renal injury was more severe in AAI-treated Trp53(−/−) mice relative to Trp53(+/+) and Trp53(+/−) mice. Interestingly, these findings contrast with a previous study in which Trp53(+/+) mice treated daily with 10 mg/kg bw AA over 3 days presented with more severe kidney damage in comparison to Trp53(−/−) mice (Zhou et al. 2010). Moreover, the study by Zhou et al. (2010) demonstrated that AA-exposed Trp53(+/+) mouse kidney tissues present with high levels of apoptosis. Based on in vitro experiments in rat kidney tubular epithelial NRK-52E cells, the authors concluded that AA-induced apoptosis is activated by STAT3 (signal transducer and activator of transcription 3)-mediated phosphorylation of Trp53 (Zhou et al. 2010). Several reasons could explain why an opposite trend was observed in the study by Zhou et al. (2010). For example, a different mouse strain (i.e. C57BL/6-Tyrc) was used, and the mutant Trp53 mice were tagged with a gene that differentiates Trp53 genotypes according to coat colour. Biological outcomes could also be affected by the fact that Zhou et al. (2010) used the natural plant extract AA, which contains a mixture of AAI (65%) and AAI (27%), whereas pure AA was used in the present study. This should not majorly affect findings as AAI, rather than
AAII, is considered to be the nephrotoxic component of AA (Sato et al. 2004; Shibutani et al. 2007). However, it can be speculated that the observed differences are related to dose. Zhou et al. (2010) used a higher daily dose of AA (10 mg/kg bw) compared to the present study (3.5 mg/kg bw AA daily). Since p53 plays a major role in apoptotic pathways (Vousden 2000), it could be that p53 protects from AAII-induced cellular stress at lower doses (e.g. through a DNA
The impact of Trp53 status on biochemical markers of nephrotoxicity after AAI treatment

Renal damage can be monitored by different means. For example, low molecular weight proteins can be measured in urine, since damaged proximal tubular cells are unable to reabsorb these (Lebeau et al. 2005). Low molecular weight proteins found in urine include β2-microglobulin, cystatin C, Clara cell protein, retinal-binding protein and α1-microglobulin (Kabanda et al. 1995). Such proteins can be released from different areas of the proximal tubular epithelium after AAI-induced nephrotoxicity (Lebeau et al. 2005). LAP is an example of an enzyme that is used experimentally to monitor AA-induced renal damage and it tends to be excreted from the brush border membrane of the proximal tubule. In the present study, LAP activity increased at 6 days, particularly in urine of AA-treated Trp53(+/−) mice. This can be explained by the fact that AAI-exposed Trp53(+/−) proximal tubules presented with detachment of the brush border membrane and necrosis. LAP activity in urine of AAI-treated Trp53(−/−) mice also seemed to be higher. However, the activity of the enzyme was not as high as for AAI-exposed Trp53(+/−) urine, and this change was not statistically significant. This can be explained by the fact that atrophic Trp53(−/−) proximal tubules are unable to regenerate the brush border membrane and, consequently, cannot secrete LAP as Trp53(+/+) cells. Other studies also showed that LAP activity increases following AA treatment. For example, LAP activity increased in the urine of rats treated daily with 10 mg/kg bw AA for 3 and 7 days (Lebeau et al. 2005). However, LAP activity decreased after day 7 in AA-treated rats. Other studies also showed that LAP activity increases up to a certain period of AA treatment (Debelle et al. 2002, 2003), suggesting that LAP activity is a marker of acute AA-induced nephrotoxicity.

Measuring creatinine in serum is another method with which to monitor renal function (Debelle et al. 2003). Creatinine results from creatinine phosphate metabolism and it is kept at a constant rate through glomerular filtration (Duquesne et al. 2017; Klawitter et al. 2010). If such filtration is affected through damage, creatinine accumulates in the blood and decreases in the urine. Previous studies in fact showed that treatment with AA increases serum creatinine levels in rats (Debelle et al. 2002, 2003; Lebeau et al. 2005). In the present study, creatinine levels increased in Trp53(+/+), Trp53(+/−) and Trp53(−/−) serum after 6 days of AAI treatment, thus reflecting the kidney injury observed by histopathology. There was a trend to observe higher creatinine levels in serum obtained from AAI-treated Trp53(−/−) mice, which is in line with the increased kidney damage observed in such mice.
The impact of Trp53 status on the metabolome after AAI treatment

Metabonomics is a branch of “-omics” technologies whereby changes in the metabolome of an organism can be determined by analysing tissues and biofluids (e.g. urine, blood, cell medium) (Keun and Athersuch 2011; Nicholson et al. 2002). NMR is advantageous as it is simple, non-destructive and non-invasive, and it can be used to analyse complex mixtures (Beckonert et al. 2007; Chatham and Blackband 2001; Keun and Athersuch 2011). A disadvantage of NMR, however, is that it is less sensitive than other metabonomic methods, such as GC–MS (Chatham and Blackband 2001; Lenz and Wilson 2007). The advantage of the latter method is that global metabolic profiles can be compared to commercial databases (Lenz and Wilson 2007).

Interestingly, urine-related NMR spectra reflect the areas of the kidney that are subject to injury (Nicholson et al. 2002). For example, damage to proximal tubules (in the renal cortex) is linked to abnormal levels of creatinine, glucose, alanine and valine in urine. However, abnormal lactate and alanine levels in urine are characteristic of glomerular-related damage. Moreover, xenobiotics that target the renal medulla give rise to a different metabolic fingerprint to those that damage the renal cortex (Neild et al. 1997). These conclusions are based on rodent studies in which animals were treated with different toxicaants that target the kidney in a region-specific manner. For example, a rat study of mercury(II) chloride, a proximal tubular toxicant, revealed aminoaciduria (e.g. alanine, glutamine, valine) and lactic aciduria (Gartland et al. 1988).

Under normal physiological conditions, amino acids (e.g. alanine), glucose and lactate are reabsorbed throughout the proximal tubule (Bellomo 2002; Curthoys and Moe 2014). Interestingly, glucose reabsorption is attributed to the action of glucose transporters (e.g. glucose transporter 1) located in proximal tubular membranes (Rahmoune et al. 2005). Hence, if such tubules and their membranes are damaged, glucose will leak into the urine. This also applies to amino acids and lactate. The latter metabolite is in fact associated with proximal tubular damage and necrosis (Hauet et al. 2000). In the present study, alanine, glucose and lactate levels were strikingly higher in the urine of Trp53(+/+), Trp53(+/−) and Trp53(−/−) mice after 6 days of AAI treatment, indicating aminoaciduria, glycosuria and lactic aciduria, respectively. This is in line with recent findings in which urine from AAI-treated rats (75 mg/kg bw) demonstrated a similar metabolic fingerprint (Duquesne et al. 2017). In addition, high levels of glucose were previously found in rats treated with 10 mg/kg bw AA (Debelle et al. 2002). Lactic aciduria could potentially indicate the induction of anaerobic respiration in response to a lack of glucose or glomerular damage in the kidney (Duquesne et al. 2017).

However, in the present study, the glomeruli in AA-exposed kidneys seemed normal.

In the present study, succinate decreased in the urine of AAI-treated Trp53(+/+), Trp53(+/−) and Trp53(−/−) mice. This metabolite is a citric acid cycle intermediate and its reduction was noted previously in AAI-treated rats (Duquesne et al. 2017). Its reduction in urine could be explained by a dampened citric acid cycle. Trimethylamine is produced by intestinal bacteria in humans (e.g. from choline) and can be ingested through the diet (Zeisel and Warrier 2017). The reduction of trimethylamine in the urine of AAI-treated Trp53(+/+), Trp53(+/−) and Trp53(−/−) mice could thus be an indication of lower food consumption. In fact, mice treated with AAI for 6 days displayed early signs of sickness, which is normally associated with a decrease in appetite. Previous work on rats noted a decrease in food consumption following AAI treatment relative to controls (Duquesne et al. 2017). However, in the present study, insignificant changes in body weight after 6 days of AAI treatment could indicate that a decrease in trimethylamine levels is unrelated to dietary changes.

Overall, certain urinary metabolites (e.g. glucose) clearly acted as biomarkers for AAI-induced nephrotoxicity. Despite the lack of a statistically significant Trp53 genotype-dependent response on urinary metabolite levels in AAI-treated mice, it can be speculated that some sort of a pattern emerges when looking closely at all the investigated metabolites. More precisely, urinary metabolite levels increased from AAI-treated Trp53(+/+) to Trp53(−/−) mice (especially for alanine, glucose and lactate). This observation would reflect the more severe injury observed in AAI-treated Trp53(−/−) mice compared to AAI-treated Trp53(+/+) mice. A larger mouse study could possibly be required to observe clear differences between genotypes (Halouska et al. 2013; Marshall and Powers 2017).

AAI-induced changes in the metabolome were also investigated in AA-exposed Trp53(+/+), Trp53(+/−) and Trp53(−/−) kidneys by GC–MS. Overall, findings showed that AAI treatment alters the quantity of certain metabolites in kidney tissues. However, Trp53 status did not majorly contribute to metabolite level alterations. Two metabolites that play a role in metabolising dietary tryptophan, 3-indolelactic acid 2 and xanthurenic acid, increased in all kidney samples after AAI treatment. Both indole and xanthurenic acid play a role in the kynurenine pathway of tryptophan metabolism (Badawy 2017). Interestingly, previous work on AA-exposed human renal proximal tubular HK-2 cells showed that AA affects tryptophan metabolism (Liu et al. 2016). In the present study, amino acid levels also increased in AAI-exposed kidneys. These amino acids included l-allothreonine 1, l-leucine 1, l-lysine 2, l-threonine 1 and norvaline 1, thus indicating some sort of shift in amino acid metabolism after AAI treatment.
Previous studies on rat urine demonstrated that AA treatment leads to increased amino acid levels (Hu et al. 2017; Ni et al. 2007). Citric acid also increased strikingly in AAI-treated kidneys. It could be that citric acid levels in tissue are associated with changes in acidosis and alkalosis (Curthoys and Moe 2014; Relman 1972). Interestingly, the effect on citric acid levels was more prominent in tissues than in urine after AAI treatment. However, a definite explanation cannot be given as to why citric acid levels increased in tissue, since a significant increase in other citric acid cycle intermediates was not noted in AAI-exposed kidneys. Uric acid is a product of nucleotide metabolism and hippuric acid plays a role in both tryptophan and phenylalanine metabolism (Hu et al. 2017). Both these metabolites increased in AAI-exposed kidneys. These were previously identified as biomarkers of AA exposure in rodents (Hu et al. 2017; Zhao et al. 2015a). It has been previously shown that kidney injury unrelated to AAI exposure can lead to changes in nucleotide metabolism, especially purine metabolism (Wei et al. 2014). However, a decrease in the levels of the nucleotide cytidine-5′-monophosphate 1 in AAI-exposed kidneys indicated that AAI treatment impacts on pyrimidine metabolism. Further investigations would be required to determine the significance of AAI-induced perturbations in nucleotide metabolism in vivo. AA exposure can perturb lipid and fatty acid metabolism, which can in turn be linked to inflammation (Lou et al. 2011; Zhao et al. 2015b). In the present study, methyl palmitate decreased in AAI-exposed kidneys. This does not concur with a previous GC–MS study in which palmitate levels increased in kidneys isolated from rats treated with AA (10 and 20 mg/kg bw daily for 7 days) (Lou et al. 2011). It could be that an opposite trend in methyl palmitate levels was observed in the present study because the dosage of AA was lower and signs of inflammation were not observed by histopathology. Nonetheless, a decrease in methyl palmitate levels indicated a shift in fatty acid metabolism.

Overall, GC–MS analysis of kidney tissues did not fully mirror the findings obtained with urine by NMR. However, metabolite perturbations in kidneys revealed that AAI-treated mice exhibit changes in metabolites that play a role in tryptophan, amino acid, nucleotide and fatty acid metabolism.

The impact of Trp53 status on AAI bioactivation and DNA damage in vivo

To elucidate the role of Trp53 in AAI bioactivation in vivo, DNA damage (i.e. AAI-DNA adduct formation) was investigated in livers (non-target organs) as well as kidneys and bladders (both target organs). Liver and kidney in particular play important roles in AAI metabolism (Stiborova et al. 2013, 2014a). In the present study, the formation of DNA adducts was highest in kidneys, which is in agreement with a number of studies in which mice were treated acutely or sub-chronically with AAI (Arlt et al. 2011b, 2017; Shibutani et al. 2007; Stiborova et al. 2012). However, Trp53 genotype had no impact on AAI-DNA adduct formation in vivo despite the impact of Trp53 genotype on AAI-induced renal injury. These in vivo results do not support in vitro findings where TP53 genotype clearly impacted on AAI-induced DNA adduct formation (Simoes et al. 2008). However, Trp53 could, however, still impact on the bioactivation of AAI through another mechanism.

Expression of p53 protein was not detected in untreated (control) and AAI-exposed Trp53(+/+), Trp53(+/−) and Trp53(−/−) kidneys. The findings are in line with previous work in which p53 was not detected in untreated (control) and AAI-exposed (5 mg/kg bw AAI daily for 3, 12 and 21 days) TP53(+/+) Hupki mouse kidneys (Arlt et al. 2011b). p53 protein is also not detected in normal kidney tissue in humans (HPA 2018), but p53 induction has been observed in urothelial tumours of AAN patients (Cosyns et al. 1999). On the other hand, AAI exposure resulted in the induction of p53 in TP53(+/+) HCT116 cells (Simoes et al. 2008), suggesting that AAI exposure may impact differently on the cellular accumulation of p53 in vitro and in vivo. Other DDR proteins were also investigated. p21, a major target of p53 (Kruiswijk et al. 2015), was weakly induced in Trp53(+/−), Trp53(+/−) and Trp53(−/−) kidneys. This is in accordance with a previous study in which AAI-exposed (5 mg/kg bw daily) TP53(+/+) Hupki kidneys exhibited p21 induction only after 12 and 21 days, but not 3 days of treatment (Arlt et al. 2011a). Nevertheless, the observed p21 induction was higher at 12 days than what was found in this study at 6 days, potentially indicating that prolonged treatment with AAI is required to detect significant changes in p21 expression. AAI has also been shown to induce the formation of DNA strand breaks in cells and H2ax is used as a marker for double-strand breaks (Chen et al. 2010; Dickey et al. 2009). In the present study, H2ax induction was highest in kidneys of AAI-treated Trp53(−/−) mice, thus going in hand with the proximal tubular injury observed in such tissues.

AAI is activated and detoxified by several enzymes, which include NQO1 and CYP1A1 (Stiborova et al. 2013, 2014a). We utilised multiple approaches (i.e. protein expression, enzyme activity and gene expression) to study the potential impact of Trp53 on AAI bioactivation in the kidney. NQO1 is the most potent cytosolic enzyme capable of catalysing the bioactivation of AAI (Barta et al. 2014; Stiborova et al. 2011, 2014b). Here, Nqo1 protein expression increased in AAI-exposed Trp53(+/+) and Trp53(+/−) kidney cytosols. This induction of Nqo1 protein in kidney...
tissue has been previously shown in mice treated with AAI (Arlt et al. 2011b; Barta et al. 2014). In the present study, it could be argued that Nqo1 expression was unaffected by AAI treatment in Trp53(−/−) kidney cytosols, thus indicating a Trp53-dependent response on Nqo1 expression. A similar effect was observed for Nqo1 gene expression, whereas this response was less pronounced when measuring Nqo1 enzyme activity. Collectively, these findings indicate that any Trp53 genotype-dependent impact on Nqo1 activity does not lead to a substantial alteration of AAI bioactivation; hence, no differences were observed in DNA adduct formation between AAI-exposed Trp53(+/+), Trp53(+/−) and Trp53(−/−) kidneys.

Enzymes of the CYP1A family (i.e. CYP1A1 and CYP1A2) play an important role in AAI metabolism due to their dual role in AAI activation and detoxication (Levoya et al. 2011). Furthermore, previous studies showed that Cyp1a1 and Cyp1a2 are expressed in proximal tubular cells (Schaaf et al. 2001). The responses on Cyp1a1/2 in the present study were complex, which could be linked to the fact that the observed effects were small or absent. The lack of Cyp1a1 protein expression could be explained by the fact that the Cyp1a1 antibody used may not be sensitive enough to detect low Cyp1a1 levels. Cyp1a activity was Trp53 genotype-dependent in AAI-exposed kidneys, but generally responses differed between untreated (control) and AAI-exposed Trp53(+/−), Trp53(+/−) and Trp53(−/−) kidney microsomes. Overall, Cyp1a activity in kidneys was low, indicating that this enzyme might not contribute to AAI metabolism in these tissues. This was further confirmed by investigating Cyp1a1 expression in kidney tissue. Again, these findings are in accord with the fact that no differences were observed in DNA adduct formation between AAI-exposed Trp53(+/−), Trp53(+/−) and Trp53(−/−) kidneys.

The impact of Trp53 status on AAI bioactivation in vitro

The lack of influence of Trp53 genotype on AAI-induced DNA adduct formation in vivo does not support previous in vitro findings where Trp53 genotype clearly impacted on AAI bioactivation (i.e. AAI-DNA adduct formation) in human cells (Simoes et al. 2008). To further test the hypothesis that p53 influences AAI bioactivation in vitro, the genotoxic effects of AAI were investigated in Trp53(+/−), Trp53(+/−) and Trp53(−/−) MEFs. Cell viability in these MEFs decreased in a concentration-dependent manner. This was shown in other studies using MEFs and confirmed the previously characterised cytotoxicity of AAI (Krais et al. 2015). AAI-DNA adduct levels in Trp53(+/−), Trp53(+/−) and Trp53(−/−) MEFs suggested that AAI bioactivation might be Trp53-dependent in this mouse in vitro model. More precisely, at 48 h, DNA adducts were lower in AAI-exposed Trp53(−/−) MEFs relative to Trp53(+/+) MEFs. Interestingly, this finding reflects observations in AAI-exposed HCT116 cells (i.e. higher adduct levels in TP53(+/-) cells relative to TP53(−/−) cells), although the underlying mechanism has not yet been elucidated in these cells (Simoes et al. 2008).

Nqo1 expression was investigated in AAI-exposed Trp53(+/+), Trp53(+/−) and Trp53(−/−) MEFs. The induction of Nqo1 at the protein level was found to be Trp53-dependent, with the highest induction occurring in Trp53(+/−) and Trp53(+/−) MEFs. No changes were observed in AAI-exposed Trp53(−/−) MEFs. The mRNA data for Nqo1 also demonstrated Trp53-dependent changes (particularly at 48 h). As shown at the protein level, Nqo1 expression was at its lowest in Trp53(−/−) MEFs. Since the expression of Nqo1 correlated with AAI-DNA adduct levels, a novel role for Trp53 in AAI bioactivation was identified. The findings for Nqo1 also mirror those found in vivo.

Conclusions

The in vivo findings in this study indicate that WT Trp53 protects against AAI-induced nephrotoxicity. Measuring markers of nephrotoxicity (i.e. LAP and serum creatinine) and urinary metabolites did not show a clear-cut Trp53 genotype-dependent response. The histopathological and biochemical observations are supported by the metabolic measurements, where a consistent Trp53 genotype-dependent trend was observed for a number of urinary metabolites, but with high inter-individual variability. Performing GC–MS analysis on kidney tissues showed metabolic pathways that may be affected by AAI treatment, but Trp53 status did not clearly impact on such metabolic profiles. Nevertheless, discovering a Trp53 genotype-dependent response on proximal tubular damage prompted further studies to explore the mechanisms by which Trp53 affects AAI-induced DNA damage. The findings underlined the DNA damaging properties of AAI but showed that Trp53 status has no impact on AAI-induced DNA adduct formation. Trp53 genotype did not significantly impact on Cyp1a1 and Nqo1 in AAI-exposed kidneys, indicating that p53 function does not modulate AAI metabolism in vivo. As Trp53 status clearly impacted on AAI-induced nephrotoxicity, the underlying mechanism(s) cannot be explained by differences in AAI genotoxicity and remains to be further explored.

The in vitro study indicated that Trp53 impacts on Nqo1 expression after AAI exposure and supported the in vivo findings. Potential mechanisms by which Trp53 regulates or influences the induction of Nqo1 remain to be further investigated. In this context, it is noteworthy that polymorphisms in the human NQO1 gene have been reported to be important in BEN patients and the NQO1*2 (C609T) genotype
predisposed BEN patients to the development of urothelial cancer (Stiborova et al. 2016; Toncheva et al. 2004). Given the importance of TP53 mutations in cancers arising from AA exposures (Chen et al. 2012; Grollman et al. 2007; Lord et al. 2004), it would also be crucial to further investigate the role of p53 in AAI bioactivation with other in vitro models. These could include human HCT116 cells with differing TP53 genotypes (including TP53 mutants) (Wohak et al. 2016) and MEFs bearing TP53 mutations relevant to AAI carcinogenesis (Odell et al. 2013). Mouse models carrying specific TP53 mutations frequently observed in human tumours are also available to further explore the impact of mutant TP53 on AAI-induced nephrotoxicity and DNA damage (Song et al. 2007).

Acknowledgements Work at King’s College London was supported by Cancer Research UK (Grant C313/A14329). Mateja Borcisa was supported by a PhD studentship from the MRC-PHE Centre for Environment and Health. The authors thank Dr. Mirjam Luijk from the National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands, for providing the Trp53 knock-out mouse model.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Arlt VM, Ferluga D, Stiborova M et al (2002a) Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? Int J Cancer 101(5):500–502. https://doi.org/10.1002/ijc.10602
Arlt VM, Stiborova M, Schmeiser HH (2002b) Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 17(4):265–277. https://doi.org/10.1093/mutagen/e17.4.265
Arlt VM, Stiborova M, Henderson CJ et al (2008) Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice. Carcinogenesis 29(3):656–665. https://doi.org/10.1093/carcin/bgn002
Arlt VM, Levova K, Barta F et al (2011a) Role of P450 1A1 and P450 1A2 in bioactivation versus detoxification of the renal carcinogen aristolochic acid I: studies in Cyp1a1−/−, Cyp1a2−/−, and Cyp1a1/1a2−/− mice. Chem Res Toxicol 24(10):1710–1719. https://doi.org/10.1021/tr200259y
Arlt VM, Zuo J, Trenz K et al (2011b) Gene expression changes induced by the human carcinogen aristolochic acid I in renal and hepatic tissue of mice. Int J Cancer 128(1):21–32. https://doi.org/10.1002/ijc.25324
Arlt VM, Meinel W, Florian S et al (2017) Impact of genetic modulation of SULT1A enzymes on DNA adduct formation by aristolochic acids and 3-nitrobenzanthrone. Arch Toxicol 91(4):1957–1975. https://doi.org/10.1007/s00204-016-1808-6
Badawy AA (2017) Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects. Int J Tryptophan Res 10:1–20. https://doi.org/10.1177/1178646917691938
Bakhyia N, Arlt VM, Bahn A, Burckhardt G, Phillips DH, Glatt H (2009) Molecular evidence for an involvement of organic anion transporters (OATs) in aristolochic acid nephropathy. Toxicology 264:74–79. https://doi.org/10.1016/j.tox.2009.07.014
Barta F, Levova K, Frei E, Schmeiser HH, Arlt VM, Stiborova M (2014) The effect of aristolochic acid I on expression of NAD(P)H:quinone oxidoreductase in mice and rats—a comparative study. Mutat Res 768:1–7. https://doi.org/10.1016/j.mrger.2014.01.012
Baudoux TE, Pozdzik AA, Arlt VM et al (2012) Probencid prevents acute tubular necrosis in a mouse model of aristolochic acid nephropathy. Kidney Int 82(10):1105–1113. https://doi.org/10.1038/kij.2012.264
Becknert O, Keun HC, Ebbels TM et al (2007) Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, and tissue extracts. Nat Protoc 2(11):2692–2703. https://doi.org/10.1038/nprot.2007.376
Bellomo R (2002) Bench-to-bedside review: lactate and the kidney. Crit Care 6(4):322–326. https://doi.org/10.1186/cc1518
Brosh R, Rotter V (2009) When mutants gain new powers: news from TP53. Crit Care 6(4):322–326. https://doi.org/10.1186/cc1518
 consumes acidosis. Clin J Am Soc Nephrol 9(9):1627–1638. https://doi.org/10.2215/CIN.10931012
Debellle FD, Nortier JL, De Prez EG et al (2002) Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats. J Am Soc Nephrol 13:431–436
Debellle FD, Nortier JL, Nortier et al (2003) Effects of defenfluramine on aristolochic acid nephrotoxicity in a rat model for Chinese-herb nephropathy. Arch Toxicol 77(4):218–226. https://doi.org/10.1007/s00204-003-0438-y
Dicyk JS, Redon CE, Nakamura AJ, Baird BJ, Seidelinkaova OA, Bonner WM (2009) H2AX: functional roles and potential applications. Chromosoma 118(6):683–692. https://doi.org/10.1007/s00412-009-0234-4
Dickman KG, Sweet DH, Bonala R, Ray T, Wu A (2011) Physiological and molecular characterization of aristolochic acid transport by the kidney. J Pharmacol Exp Ther 338(2):588–597. https://doi.org/10.1124/jpet.111.180984

Springer
Shibutani S, Dong H, Suzuki N, Ueda S, Miller F, Grollman AP (2007)

Sherr CJ, De Pinho RA (2000) Cellular senescence as a tumor-suppressor mechanism. Cell 102:407–410. https://doi.org/10.1016/S0092-8674(00)00465-5

Shibutani S, Dong H, Suzuki N, Ueda S, Miller F, Grollman AP (2007) Selective toxicity of aristolochic acids I and II. Drug Metab Dispos 35(7):1217–1222. https://doi.org/10.1124/dmd.107.014688

Simoes ML, Hockley SL, Schwerdtle T et al (2008) Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53 [and erratum 2018, 344, 75]. Toxicol Appl Pharmacol 232(1):86–98. https://doi.org/10.1016/j.taap.2008.06.006

Song H, Hollstein M, Xu Y (2007) p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 9(5):573–580. https://doi.org/10.1038/nclb1571

Stiborova M, Mares J, Frei E, Arlt VM, Martinek V, Schmeiser HH (2011) The human carcinogen aristolochic acid i is activated to form DNA adducts by human NAD(P)H:quinone oxidoreductase without the contribution of acetyltransferases or sulfotransferases. Environ Mol Mutagen 52(6):448–459. https://doi.org/10.1002/em.20642

Stiborova M, Levova K, Barta F et al (2012) The influence of dicoumarol on the bioactivation of the carcinogen aristolochic acid in rats. Mutagenesis 29(3):189–200. https://doi.org/10.1093/toxsci/kfr306

Stiborova M, Levova K, Barta F et al (2014b) The impact of p53 function on the metabolic activation of the carcinogenic air pollutant 3-nitrobenzanthrone and its metabolites 3-aminobenzanthrone and 3-hydroxy-3-aminobenzanthrone in human cells. Mutagenesis 33(4):311–321. https://doi.org/10.1093/mutage/gey025

Stiborova M, Arlt VM, Schmeiser HH (2016) Balkan endemic nephropathy: an update on its aetiology. Arch Toxicol 90(11):2595–2615. https://doi.org/10.1007/s00204-016-1819-3

Stiborova M, Arlt VM, Schmeiser HH (2017) DNA adducts formed by aristolochic acid are unique biomarkers of exposure and explain the initiation phase of upper urothelial cancer. Int J Mol Sci 18(10):1–19. https://doi.org/10.3390/ijms18102144

Taneja P, Zhu S, Maglic D, Fry EA, Kendig RD, Inoue K (2011) Transgenic and knockout mice models to reveal the functions of tumor suppressor genes. Clin Med Insights Oncol 5:235–257. https://doi.org/10.4137/CMO.S7516

Toncheva DI, Von Ahsen N, Atanasova SY, Dimitrov TG, Armstrong VW, Oellerich M (2004) Identification of NQO1 and GSTs genotype frequencies in Bulgarian patients with Balkan endemic nephropathy. J Nephrol 17(3):384–389

Turesky RJ, Yun BH, Brennan P et al (2016) Aristolochic acid exposure in Romania and implications for renal cell carcinoma. Br J Cancer 114(1):76–80. https://doi.org/10.1038/bjc.2015.402

Vousden KH (2000) p53: death star. Cell 103:691–694. https://doi.org/10.1016/S0092-8674(00)00171-9

Vousden KH, Lane DP (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8(4):275–283. https://doi.org/10.1038/nrm2147

Wei Q, Xiao X, Fogle P, Dong Z (2014) Changes in metabolic profiles during acute kidney injury and recovery following ischemia/reperfusion. PLoS One 9(9):1–13. https://doi.org/10.1371/journal.pone.0106647

Willis AJ, Indra R, Wohak LE et al (2018) The impact of chemotherapeutic drugs on the CYP1A1-catalysed metabolism of the environmental carcinogen benzo[a]pyrene: effects in human colorectal HCT116 TP53(+/-), TP53(+/+) and TP53(+-/-) cells. Toxicology 398–399:1–12. https://doi.org/10.1016/j.tox.2018.02.006

Wohak LE, Krais AM, Kucab JE et al (2016) Carcinogenic polycyclic aromatic hydrocarbons induce CYP1A1 in human cells via a p53-dependent mechanism. Arch Toxicol 90(2):291–304. https://doi.org/10.1007/s00204-014-1409-1

Wohak LE, Baranski AC, Krais AM, Schmeiser HH, Phillips DH, Arlt VM (2018) The impact of p53 function on the metabolic activation of the carcinogenic air pollutant 3-nitrobenzanthrone and its metabolites 3-aminobenzanthrone and N-hydroxy-3-aminobenzenanthrone in human cells. Mutagenesis 33(4):311–321. https://doi.org/10.1093/mutage/gey025

Wohak LE, Monien B, Phillips DH, Arlt VM (2019) Impact of p53 function on the sulfotransferase-mediated bioactivation of the alkylated polycyclic aromatic hydrocarbon 1-hydroxymethylpyrene in vitro. Environ Mol Mutagen 1002.https://doi.org/10.2174/1389200211314060006

Xue X, Gong LK, Maeda K et al (2011) Critical role of organic anion transporters 1 and 3 in kidney accumulation and toxicity of aristolochic acid I. Mol Pharm 8(6):2183–2192. https://doi.org/10.1021/mp100418u

Zeilis SH, Warrier M (2017) Trimethylamine N-oxide, the microbiome, and heart and kidney disease. Ann Rev Nutr 37:157–181. https://doi.org/10.1146/annurev-nutr-071816-064732

Zhao YY, Wang HL, Cheng XL et al (2015b) Metabolomics analysis reveals the association between lipid abnormalities and oxidative stress, inflammation, fibrosis, and Nrf2 dysfunction in aristolochic acid-induced nephropathy. Sci Rep 5:1–13. https://doi.org/10.1038/srep12936

Zhou L, Fu P, Huang XR, Liu F, Lai KN, Lan HY (2010) Activation of p53 promotes renal injury in acute aristolochic acid nephropathy. J Am Soc Nephrol 21(1):31–41. https://doi.org/10.1681/ASN.2008111133

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.